James R Carlyle Selected Research

Infections

1/2021	Targeting cellular fatty acid synthesis limits T helper and innate lymphoid cell function during intestinal inflammation and infection.
1/2020	Tetramer Immunization and Selection Followed by CELLISA Screening to Generate Monoclonal Antibodies against the Mouse Cytomegalovirus m12 Immunoevasin.
12/2019	Mouse Cytomegalovirus m153 Protein Stabilizes Expression of the Inhibitory NKR-P1B Ligand Clr-b.
1/2019	Mouse cytomegalovirus-experienced ILC1s acquire a memory response dependent on the viral glycoprotein m12.
1/2018	The Tumor Necrosis Factor Superfamily Member RANKL Suppresses Effector Cytokine Production in Group 3 Innate Lymphoid Cells.
1/2017	Interferon-Dependent Induction of Clr-b during Mouse Cytomegalovirus Infection Protects Bystander Cells from Natural Killer Cells via NKR-P1B-Mediated Inhibition.
1/2016	Expansion and Protection by a Virus-Specific NK Cell Subset Lacking Expression of the Inhibitory NKR-P1B Receptor during Murine Cytomegalovirus Infection.
1/2015	Modulation of Clr Ligand Expression and NKR-P1 Receptor Function during Murine Cytomegalovirus Infection.
1/2014	Complexity and Diversity of the NKR-P1:Clr (Klrb1:Clec2) Recognition Systems.
5/2012	Poxvirus infection-associated downregulation of C-type lectin-related-b prevents NK cell inhibition by NK receptor protein-1B.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James R Carlyle Research Topics

Disease

10	Infections 01/2021 - 05/2012
9	Neoplasms (Cancer) 01/2023 - 07/2002
3	Inflammation (Inflammations) 11/2022 - 10/2017
3	Virus Diseases (Viral Diseases) 01/2019 - 05/2012
2	COVID-19 06/2023 - 01/2022
1	Pulmonary Alveolar Proteinosis 11/2022
1	Pneumococcal Infections 11/2022
1	Colitis 01/2021
1	Lymphoma (Lymphomas) 01/2018
1	Leukemia 01/2018
1	Poxviridae Infections 05/2012
1	Experimental Melanoma 06/2008
1	Confusion (Bewilderment) 06/2006

Drug/Important Bio-Agent (IBA)

8	LigandsIBA 12/2019 - 07/2002
3	Interleukin-22 (IL-22)IBA 01/2021 - 10/2017
3	C-Type Lectins (C-Type Lectin)IBA 01/2014 - 06/2008
2	VaccinesIBA 06/2023 - 01/2022
2	BNT162 VaccineIBA 06/2023 - 01/2022
2	Transcription Factors (Transcription Factor)IBA 01/2023 - 01/2019
2	Granzymes (Granzyme)IBA 01/2023 - 01/2016
2	EnzymesIBA 01/2021 - 01/2019
2	CytokinesIBA 01/2019 - 10/2017
1	LipidsIBA 11/2022
1	Surface-Active Agents (Surfactants)IBA 11/2022
1	Pulmonary Surfactants (Pulmonary Surfactant)IBA 11/2022
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2021
1	Acetyl-CoA CarboxylaseIBA 01/2021
1	soraphen AIBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	Natural Killer Cell ReceptorsIBA 12/2019
1	X-Box Binding Protein 1IBA 01/2019
1	Glycoproteins (Glycoprotein)IBA 01/2019
1	Inositol (Myoinositol)IBA 01/2019
1	Chemokine ReceptorsIBA 01/2018
1	Interleukin-17 (Interleukin 17)IBA 01/2018
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2018
1	Histocompatibility Antigens Class IIBA 01/2018
1	InterferonsIBA 01/2017
1	NK Cell Lectin-Like Receptor Subfamily BIBA 01/2015
1	Pattern Recognition ReceptorsIBA 01/2015
1	Membrane Proteins (Integral Membrane Proteins)IBA 05/2012
1	Messenger RNA (mRNA)IBA 05/2012
1	AntigensIBA 06/2008
1	Peptides (Polypeptides)IBA 06/2008
1	Isoantigens (Alloantigen)IBA 06/2006

Therapy/Procedure

2	Therapeutics 01/2018 - 06/2008